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The EU regulatory framework provides opportunities for
increased flexibility and speed for Orphan Medicinal
Product (OMP) marketing authorisations. Nevertheless
the yearly rate of OMP approvals is not increasing [1]
and available tools and procedures are used infrequently.
According to a review of approval timelines from 2001-
2010 [2], FDA median total review time for OMPs (235
days) was almost 5 months faster than the median EMA
review time (381 days). Furthermore, FDA approves
OMPs 87 days faster than novel therapies overall, whereas
EMA takes 15 days longer. One driver for this striking dif-
ference between FDA and EMA review time for OMPs
seems to be FDAs granting of a Priority Review which was
the case for 78% of orphan product applications between
2006 and 2010 [3]. An Accelerated Review at EMA was
granted only for ~3% of approved OMPs since 2001 [4].
Conditional Marketing Authorisation (CMA) is another
tool that could help shorten time to availability of new
OMPs, unfortunately only ~5% of approved OMPs have
benefited so far [4].
Early dialogue and agreement between the applicant and
EMA scientific bodies on required data would allow more
timely alignment and predictability, thus supporting
increased use of Accelerated Review and CMA. Coupled
with more flexibility on study design for OMPs, e.g.,
greater acceptance of surrogate endpoints, single well-
controlled trials, and data packages supplemented with
post-marketing and compassionate-use data, this would
create a more favourable environment for OMP approvals
in the EU.
Other approaches for speedier OMP approval should
be explored, including a ‘rolling application’ that would
allow initiating review of parts of the dossier prior to
validating the entire application. Additionally, increased
collaboration between EMA’s scientific bodies could
help streamline the various regulatory procedures
between orphan designation and approval, e.g. parallel
discussions with the Paediatric Committee, the Commit-
tee for Advanced Therapies and the Scientific Advise
Working Party. The success of such measures will
require a close dialogue between the applicant and
EMA. Applicants for any procedures regarding orphan
drugs would benefit from a continuous support from
EMA’s orphan drug sector as they have an in depth
understanding of the special challenges OMP developers
face.
Taking an OMP through all regulatory hurdles until
approval in a more timely manner requires increased regu-
latory flexibility and predictability. Although regulatory
procedures in the EU are working well, improvement
could be achieved by increasing the use of existing tools
and more creative thinking on conditions for approval of
OMPs in the EU.
Published: 22 November 2012
References
1. European Commissions Community Register of medicinal products for
human use. [http://ec.europa.eu/health/documents/community-register/
html/index_en.htm].
2. Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM,
Ross JS: Regulatory Review of Novel Therapeutics – comparison of three
regulatory agencies. N. Engl. J. Med 2012, 366:2284-2293.
3. Pariser AR, Slack DJ, Bauer LJ, Warner CA, Tracy LA: Characteristics of rare
disease marketing applications associated with FDA product approvals
2006-2010. Drug Discovery Today 2012, 17:898-904.




Cite this article as: Edfjäll: Leveraging existing opportunities for
improved Orphan Drug approval in the EU. Orphanet Journal of Rare
Diseases 2012 7(Suppl 2):A27.
Correspondence: cedfjaell@shire.com
Global Regulatory Affairs, Shire HGT, Eysins, 1262, Switzerland
Edfjäll Orphanet Journal of Rare Diseases 2012, 7(Suppl 2):A27
http://www.ojrd.com/content/7/S2/A27
© 2012 Edfjäll; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
